Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Free Cash Flow: 2022-2025

Historic Free Cash Flow for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$24.2 million.

  • Taysha Gene Therapies' Free Cash Flow fell 12.52% to -$24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.2 million, marking a year-over-year decrease of 7.22%. This contributed to the annual value of -$81.6 million for FY2024, which is 6.13% down from last year.
  • As of Q3 2025, Taysha Gene Therapies' Free Cash Flow stood at -$24.2 million, which was down 17.86% from -$20.6 million recorded in Q2 2025.
  • Taysha Gene Therapies' Free Cash Flow's 5-year high stood at $12.4 million during Q4 2022, with a 5-year trough of -$49.4 million in Q1 2022.
  • Moreover, its 3-year median value for Free Cash Flow was -$20.6 million (2025), whereas its average is -$20.5 million.
  • Examining YoY changes over the last 5 years, Taysha Gene Therapies' Free Cash Flow showed a top increase of 54.58% in 2023 and a maximum decrease of 230.08% in 2023.
  • Taysha Gene Therapies' Free Cash Flow (Quarterly) stood at $12.4 million in 2022, then crashed by 230.08% to -$16.1 million in 2023, then decreased by 13.46% to -$18.3 million in 2024, then fell by 12.52% to -$24.2 million in 2025.
  • Its Free Cash Flow was -$24.2 million in Q3 2025, compared to -$20.6 million in Q2 2025 and -$22.0 million in Q1 2025.